ADAMTS-5 deficient mice do not develop mechanical allodynia associated with osteoarthritis following medial meniscal destabilization.
OBJECTIVE
To characterize pain-related behavior during the course of knee osteoarthritis (OA) induced by destabilization of the medial meniscus (DMM) in wild type (WT) and in ADAMTS-5 null mice.


METHODS
DMM surgery was performed in the right knee of CD-1 mice. At regular intervals up to 8 weeks after surgery, mice were assessed for the following parameters: mechanical allodynia (via withdrawal thresholds to von Frey filaments applied to the plantar surface of both hind paws or to the tail), thermal hyperalgesia, locomotor activity and gait analysis. In addition, mechanical allodynia was tested in C57BL/6 WT or ADAMTS-5 null mice following DMM surgery.


RESULTS
In CD-1 mice, a robust and progressive decrease in withdrawal threshold was observed in both hind paws after DMM but not sham surgery. Allodynia was apparent as early as 14 days postoperatively. Both sexes developed OA changes after surgery with concurrent mechanical allodynia. No other pain-related behavioral changes were detected up to 8 weeks post-surgery. In C57BL/6 mice, a genetic background in which only males develop OA changes after DMM, males but not females developed allodynia in the ipsilateral hind paw. In contrast, C57BL/6 ADAMTS-5 null mice did not develop OA changes or mechanical allodynia up to 8 weeks post-surgery.


CONCLUSIONS
Joint pathology following DMM surgery in mice is associated with progressive mechanical allodynia. ADAMTS-5 null mice are resistant to DMM-induced OA-like lesions and to the associated mechanical allodynia.
Malfait
A M
AM
Pfizer Global Research and Development, St. Louis, MO, USA. anne-marie_malfait@rush.edu
Ritchie
J
J
Gil
A S
AS
Austin
J-S
JS
Hartke
J
J
Qin
W
W
Tortorella
M D
MD
Mogil
J S
JS
D000082:Acetaminophen / Q000627:therapeutic use; D018712:Analgesics, Non-Narcotic / Q000627:therapeutic use; D000701:Analgesics, Opioid / Q000627:therapeutic use; D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D004195:Disease Models, Animal; D018450:Disease Progression; D005260:Female; D005269:Femur / Q000473:pathology; D005684:Gait / Q000187:drug effects / Q000502:physiology; D008297:Male; D008592:Menisci, Tibial / Q000601:surgery*; D051379:Mice; D018345:Mice, Knockout; D009020:Morphine / Q000627:therapeutic use; D009043:Motor Activity / Q000187:drug effects / Q000502:physiology; D020370:Osteoarthritis, Knee / Q000188:drug therapy / Q000503:physiopathology*; D010146:Pain / Q000188:drug therapy / Q000503:physiopathology*; D013977:Tibia / Q000473:pathology; D016474:Weight-Bearing / Q000502:physiology
D018712:Analgesics, Non-Narcotic; D000701:Analgesics, Opioid; D000082:Acetaminophen; D009020:Morphine